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Abstract
Background: A dual blockade against the novel immune checkpoint inhibitor lymphocyte activation gene-3 (LAG-
3) and programmed cell death protein-1 (PD-1) is currently considered in advanced breast cancer. Nevertheless, PD-
1 or LAG-3 expression within distant metastatic breast cancer tissue remains understudied.
Methods: To address this knowledge gap, we investigated the PD-1 and LAG-3 expression in combination with the
CD8-based immune phenotype in intrapatient matched primary tumor distant metastases, representing 95 breast
cancer patients with metastases occurring at four different anatomical locations. The immune phenotype was
categorized into 2 categories: inflamed corresponding to the clinical category “hot” and exhausted or desert
consistent with clinically “cold” tumors.
Results: Metastases of “cold” primary tumors always remained “cold” at their matched metastatic site. Expression of
PD-1/LAG-3 was associated with a “hot” immune phenotype in both the primary tumors and metastases. We could
not observe any association between the immune phenotype and the breast cancer molecular subtype. Brain and
soft tissue metastases were more commonly inflamed with signs of exhaustion than other anatomical sites of
metastases. Taken together, (i) the immune phenotype varied between sites of distant metastases, and (ii) PD-1+/
LAG-3+ was strongly associated with a “hot” immune phenotype and (iii) was most prevalent in brain and soft
tissue metastases among distant metastases.
Conclusions: Our data strongly support an integrated analysis of the immune phenotype together with the PD-1/
LAG-3 expression in distant metastases to identify patients with inflamed but exhausted tumors. This may
eventually improve the stratification and likelihood for advanced breast cancer patients to profit from
immunotherapy.
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Introduction
Immunotherapy with immune checkpoint inhibitors is
usually considered in advanced metastatic breast can-
cer. The intention is to reduce the tumor burden by
restoring a durable anti-tumor immune response. As
breast cancer is not a highly immunogenic disease in
general, treatment efficacy seems to depend on the
molecular breast cancer subtype and the expression of
PD-L1 [1, 2].
Monotherapy against programmed cell death protein-1
(PD-1) showed only the modest tumor and durable re-
sponse rates in breast cancer (4–25%) [2]. In the need of
novel strategies, in vivo studies provided convincing evi-
dence that a dual blockade against PD-1 and the novel
immune checkpoint receptor lymphocyte-associated
gene-3 (LAG-3) [3] can result in tumor reduction and
increase of survival [4, 5] by restoring CD8+ T cell func-
tion [6]. In human tumor tissue, LAG-3 is co-expressed
with PD-1 on activated but exhausted CD8+ T cells [7].
Particularly, highly immunogenic tumors susceptible to
immunotherapy like melanoma, microsatellite instable
colorectal cancer, or triple-negative breast cancer carry
PD-1+/LAG-3+ CD8+ tumor-infiltrating T cells [8].
In breast cancer, the predictive value of LAG-3 expres-
sion remains still unclear. There is some prognostic evi-
dence associating high LAG-3 expression with improved
overall survival (OS) but uncertain significance with re-
spect to disease-free survival (DFS) [9]. Most ongoing
clinical trials are investigating anti-LAG-3 drugs in com-
bination with a dual blockade against PD-1 in solid tu-
mors in advanced disease with promising survival
benefits and long duration of response rates for those
who profited [5].
Interestingly, most of these trials are considering nei-
ther the amount nor the distribution of tumor-
infiltrating CD8+ T cells. For immunotherapy to be ac-
tive though, CD8+ T cells must be present within the
tumor bed—referred to as inflamed or clinically “hot” tu-
mors [10–13]. Moreover, while the advanced metastatic
disease is targeted, PD-1 and LAG-3 expression within
distant metastatic breast cancer remains understudied.
Their assessment within different anatomical sites of dis-
tant metastasis might however be crucial given that the
composition of the tumor immune microenvironment is
heterogeneous and is critically influenced by organ-
specific parenchymal cells [14–16].
To address this knowledge gap, we assessed the
CD8+ T cell immune phenotype as well as PD-1 and
LAG-3 expression in primary tumors (PBTs) with
intrapatient matched distant metastases (METs) in a
retrospective cohort of 95 breast cancer patients by
using immunohistochemistry on whole sections. Me-




We searched breast cancer patients suffering from either
invasive ductal or invasive lobular breast cancer with
hematogenous metastases in the archives of the Depart-
ment of Pathology and Molecular Pathology, University
Hospital Zurich, in the time period of 1995–2019. We
analyzed tissue material of 95 formalin-fixed paraffin-
embedded (FFPE) PBTs and their corresponding sites of
distant METs. Large parts of this cohort have been pre-
viously described [17]. Specifically, there were 49 surgi-
cal specimens and 46 biopsy specimens among the
metastatic lesions. All PBTs had been characterized for
estrogen (ER), progesterone (PR), and Her2 receptor ex-
pression either at the time of the primary diagnosis or
retrospectively. To obtain a homogenous result for ER,
PR, and Her2 receptor expression, all cases were re-
classified according to the respective ASCO guidelines
[18, 19]. Molecular breast cancer subtypes were defined
by their ER, PR, and Her2 receptor expression and their
Ki-67 proliferation rate according to the St. Gallen Con-
sensus Conference [20, 21] as follows: luminal A (ER+
and/or PR+, HER2−, Ki-67 ≤ 14%), luminal B (ER+ and/
or PR+, and/or HER2+, Ki-67 > 14%), triple-negative (ER
−, PR−, HER2−), and Her2/neu (ER−, PR−, HER2+).
Four patients were treated with preoperative chemother-
apy, and the others underwent adjuvant treatment after
surgery according to the time current guidelines and
available regimens. Distant metastasis had occurred to
either brain, bone, liver, or soft tissue with only one cor-
responding distant metastasis to each primary tumor
(Table 1). Yet, we cannot exclude that patients suffered
from additional metastatic sites not undergoing biopsy
but being monitored by imaging only. In addition to this
cohort of 95 patients, we included 43 additional breast
cancer brain metastases without a corresponding pri-
mary tumor available (Table 2). Approval of the use of
human primary breast cancer samples and metastatic
tissue was obtained from the official ethical authorities
of the Canton Zurich, Switzerland (ethical approval
KEK-2012-553), according to the Declaration of
Helsinki.
Tissue selection and immunohistochemistry
In order to assess the CD8+ T cell immune phenotype
together with PD-1/LAG-3 expression, three different
tumor compartments must be available for analysis. We
based our classification of a CD8+ T cell immune pheno-
type on their distribution within the three tumor com-
partments intratumoral, stromal, and invasive margin
[18] defined as follows: intratumoral = intraepithelial
compartment of the tumor consisting of tumor cells
without intervening intratumoral stroma, stromal =
intratumoral stroma without tumor cells, and invasive
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margin = the region centered on the border separating
the host tissue from the malignant nests, with an extent
of 1 mm. This is based on previous definitions [22] but
refines the “central tumor” compartment into an intratu-
moral and stromal compartment. Therefore, we only
studied large tissue sections of primary tumors and me-
tastases. First, we screened each case by hematoxylin
and eosin (HE) staining to assess lymphocytic infiltrate
in the three tumor compartments. Mostly, lymphocytes
were situated at the tumor margins. One tissue block
Table 1 Clinicopathological data of the 95 breast cancer patients with metastasis at either of the four anatomical locations
investigated
Clinicopathological data and group distribution of the 95 breast cancer patients with respect to the four anatomical locations at which the corresponding
intrapatient metastasis had occurred. Percentages are shown in relation to the respective metastatic site
Sobottka et al. Breast Cancer Research            (2021) 23:4 Page 3 of 11
per case was further analyzed by immunohistochemistry.
Tissue blocks were cut in multiple 2-μm sections for im-
munohistochemical stainings. Immunohistochemical
stainings of large tissue sections were performed using
automated immunostainers (Ventana Medical Systems,
Tucson, AZ, USA, or Leica BOND-III, Leica Microsys-
tems, Heerbrugg, Switzerland) utilizing the antibodies
monoclonal mouse anti-human CD8 (DAKO, clone C8/
144B, dilution 1:100), monoclonal mouse anti-human
lymphocyte activation gene 3 antibody (Abcam, clone
17B4, dilution 1:100), and monoclonal rabbit anti-
human PD-1 antibody (Cell Signaling Technologies,
clone D4W2J, dilution 1:100) with pretreatments accord-
ing to the respective manufacturers’ instructions. Anti-
body detections were performed using Refine-HRP-Kit
on BondMax Benchmark, Leica.
Classification of the CD8+ T cell immune phenotypes
To translate the distribution pattern of tumor-
infiltrating CD8+ T cells into an immune phenotype, we
first scored their spatial distribution within the primary
tumors and distant metastases according to the previ-
ously suggested consensus statement [22]. As we evalu-
ated the whole slides capturing CD8+ T cell
heterogeneity together with immunohistochemistry, we
also evaluated the intratumoral/tumor epithelial com-
partment. We defined (i) immune desert if we could not
find any CD8+ T cell in neither of the three tumor com-
partments, (ii) immune excluded if CD8+ T cells had ar-
rived at the tumor environment but could only be found
at the invasive margin or within the stromal but not
within the intratumoral compartment, and (iii) inflamed
if CD8+ T cells could be detected in the stromal com-
partment but, importantly, also in direct contact with
tumor cells meaning that they had properly infiltrated
the intratumoral compartment essential for a CD8+ T
cell-mediated cytotoxicity. Due to intratumoral hetero-
geneity, we evaluated at least three different tumor areas
per slide and considered the most common pattern as
the predominant immune phenotype. Immune pheno-
types were assessed in the first run by two pathologists
(ZV, BS) and were randomly re-assessed by one investi-
gator (BS) after a period of at least a few weeks.
Scoring of LAG-3 and PD-1
Immunohistochemistry of LAG-3 presented a dot-like
membranous staining (Fig. 2a) as also depicted by the
manufacturer and as recently described [23]. Scoring of
LAG-3 and PD-1 was performed as described recently
[23]. Any membranous positive expression of the former
within the three tumor compartments was regarded to
be sufficient to dichotomize the particular compartment
into positive or negative. To minimize bias due to tumor
heterogeneity, we evaluated three different areas per
tumor compartment of each tumor section. The average
results of these three fields per tumor compartment
were used for further evaluation. Scores were assessed in
the first run by two pathologists (ZV, BS) and were ran-
domly re-assessed by one investigator (BS) after a period
of at least a few weeks.
Statistical analysis
Associations between immune phenotypes with respect
PBTs, METs, and PD-1/LAG-3 expression were per-
formed by the Fisher-Freeman-Halton test. To this end,
immune desert and excluded tumors were summarized
into “cold” tumors and inflamed tumors were catego-
rized as “hot.” Disease-free survival (DFS) was defined as
the time between diagnosis of the PBT and the occur-
rence of the respective distant MET. While this is in
Table 2 Distant METs of “cold” PBTs remain “cold”
PBTs (left column) with an inflamed/hot immune phenotype either stayed inflamed/hot or turned cold (excluded or desert) at their matched METs (top row). In
contrast, cold/excluded PBTs (left column) always remained cold (excluded or desert) at their matched METs (top row) (A)
Among metastatic sites (left column), brain and soft tissue METs were more commonly hot/inflamed (top row) than liver and bone METs (B)
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contrast to the common perception of DFS in clinical
trials, we are convinced that this time interval may serve
as an adequate marker in the here presented exploratory
setting. Survival analysis was computed using the
Kaplan-Meier estimator. To compare the Kaplan-Meier
survival estimates, the log-rank test was applied as
Fig. 1 Immune phenotype turns “cold” in matched distant metastases irrespective of molecular subtype. Whole breast cancer tissue sections
were stained for CD8, PD-1, and LAG-3 (a). CD8+ T cells were scored semiquantitatively and assigned to the proposed immune phenotype (b).
Based on the CD8+ T cell distribution pattern within the tumor compartments, the samples were classified into “hot”/inflamed or “cold”/excluded/
desert tumors (c). An alluvial plot [24] was used to depict the distribution of immune phenotypes within the primary tumor (left) and the
corresponding distant metastases (right) among the molecular breast cancer subtypes (middle). Metastases turned into “cold” tumors irrespective
of the molecular subtype (d)
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statistical analysis. Significances are displayed as follows:
ns = p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and
****p ≤ 0.0001. Statistical analysis was performed using
the GraphPad Prism (version 7.04) and StatXact (version
12; Cytel Studio) software.
Results
Distant METs of “cold” PBTs remain “cold”
We performed immunohistochemistry for CD8, PD-1,
and LAG-3 (Fig. 1a) on whole tissue sections. To trans-
late the frequency and spatial distribution of CD8+ T
cells within the tumor compartments to a certain im-
mune phenotype, we first semiquantitatively evaluated
CD8+ T cells within PBTs and METs (Fig. 1b) to
categorize them into three immune phenotypes corre-
sponding to the clinical categories “hot” and “cold”
(Fig. 1c). In PBTs, the frequencies of immune excluded
and inflamed cases were similar. In contrast, METs
turned “cold” regardless of the breast cancer molecular
subtype as depicted using an alluvial diagram (Fig. 1d),
clinicopathological parameters, or the anatomical site of
the METs (data not shown). Interestingly, METs of
“cold” PBTs always remained “cold” at their matched
metastatic site. In contrast, “hot” PBTs either stayed
“hot” or turned “cold” in their corresponding METs
(Table 2 (A)). Among distant metastatic sites, brain and
soft tissue METs remained more commonly inflamed
(Table 2 (B)).
PD-1+/LAG-3+ expression correlates with a “hot” immune
phenotype
LAG-3 expression occurred only in PD-1-positive cases
(p < 0.01; not shown) with an overall low frequency (5%
positive intratumoral and 31% positive stromal cases in
PBTs with lower frequencies for METs). PD-1+/LAG-3+
expression correlated significantly with a “hot” immune
phenotype in both PBTs and METs (Table 3 (A and B))
regardless of the molecular breast cancer subtype (not
Table 3 Immune phenotype correlates with PD-1 and LAG-3 expression
PD-1 and LAG-3 expression correlated both in the PBTs (A) and the METs (B) with a hot/inflamed immune phenotype. PD-1 intratumoral positivity was most
predominantly overserved in brain and soft tissue METs (C)
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shown). Brain and soft tissue METs displayed more
commonly PD-1 expression with the same tendency for
LAG-3 (Table 3 (C)).
Negative prognostic disease-free survival impact of PD-1
and LAG-3 expression
The dichotomization of PBTs into inflamed/“hot” or
excluded-desert/“cold” tumors revealed an improved
disease-free survival (DFS) for “hot” PBTs (Fig. 2a). The
combined analysis of PD-1/LAG-3 expression within the
stromal tumor compartment and immune phenotype
further improved DFS discrimination: “hot” but PD-1−
PBTs displayed a significantly better DFS, while “hot”
but PD-1+ PBTs showed the same reduced DFS as “cold”
PD-1+ or PD-1− tumors (Fig. 2b, c).
PD-1+/LAG-3+ expression is associated with “hot” brain
metastases
Among distant metastatic sites, brain and soft tissues
showed more prevalently an inflamed, PD-1+/LAG-3+ im-
mune phenotype. Due to our cohort, it remained unclear
whether this effect was due to the molecular breast cancer
subtype or the brain/soft tissue-specific tumor microenvir-
onment. As the brain is commonly regarded as an
immune-privileged organ and brain metastases are clinic-
ally highly relevant, we included additional 43 breast can-
cer brain metastases (Table 4) resulting in 67 brain
metastases in total. About half of these additional brain
METs displayed a “hot” immune phenotype. Again, PD-
1+/LAG-3+ expression correlated with an inflamed im-
mune phenotype (Table 5) but was not associated with
the molecular breast cancer subtype (not shown).
Fig. 2 Negative prognostic disease-free survival impact of PD-1 and LAG-3 expression. While a “hot” immune phenotype correlated with
improved DFS (a), stromal positivity for either PD-1 or LAG-3 was associated with a worse DFS (b). The combined analysis of the immune
phenotype and PD-1/LAG-3 expression further stratified the DFS showing that “hot” but PD1−/LAG-3− cases displayed the best DFS (c)
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Discussion
By investigating a large intrapatient matched PBT distant
MET breast cancer cohort [2, 17, 25–27], we have
shown that (i) PD-1+/LAG-3+ is strongly associated with
a “hot” immune phenotype and (ii) differs between
METs and PBTs. As described, LAG-3 expression was
only observed in PD-1-positive cases [7] with an overall
low frequency [23].
For this study, we translated the intratumoral spatial
distribution pattern of CD8+ T cells into three defined
Table 4 Clinicopathological parameters of the additional 43 brain metastases
Overview of the additional cohort of breast cancer brain metastases. The primary breast cancer was not available in these cases
Table 5 PD-1 expression correlates to an inflamed phenotype in all investigated brain metastases
In the enlarged brain metastasis cohort comprising additional 43 breast cancer brain metastases to the initial 24 brain metastasis PD-1 expression also correlated
to a hot/inflamed immune phenotype
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immune phenotypes, intended to reflect the clinical
terms “hot” or “cold” tumors. We based our evaluation
on the following tumor compartments: tumor center
comprising the intratumoral/tumor epithelial and stro-
mal compartment and the invasive margin compart-
ment. While these compartments are arbitrary to a
certain extent since T cells are thought to freely move
through tissue and are as such not stuck to a particular
compartment as implied by a snap-shot-like impression
in FFPE tissue, these three compartments are well-
established and proposed as such by consensus agree-
ments [22].
As published previously [17], we evaluated the intratu-
moral compartment of the “tumor center” [22] compart-
ment based on the notion that a direct contact between
CD8+ T cells and tumor cells must occur for CD8+ T
cell-mediated cytotoxicity. Within this concept, also
metastatic biopsies containing the “tumor center” fulfill
the necessary criteria to identify immune phenotypes as
the value of the invasive margin—often lacking in meta-
static biopsy material—becomes limited. Systematic
studies assigning the spatial distribution of CD8+ T cells
to a certain immune phenotype and, moreover, validat-
ing the biological significance of these immune pheno-
types to the response to immune checkpoint inhibition
are lacking up to date. There is thus no consensus classi-
fication of immune phenotypes yet. While we are con-
vinced that our proposed immune phenotype
classification may serve as a valuable surrogate marker
also applicable in metastatic tissue, our suggested im-
mune phenotypes certainly need to be validated in a co-
hort that includes responders and non-responders to
immune checkpoint inhibition.
In contrast to the previous results, neither the immune
phenotype nor PD-1/LAG-3 expression was associated
to the molecular breast cancer subtype [28] possibly due
to the overall small number of patients in our cohort.
Overall, METs turned “cold” suggesting reduced im-
munogenicity of METs in general [25]. Interestingly,
METs of “cold” PBTs always remained “cold” at their
matched metastatic site, while “hot” PBTs either stayed
“hot” or turned “cold” in their corresponding METs.
These observations were independent of the breast can-
cer molecular subtype. While the underlying mecha-
nisms remain unclear, our findings imply a tumor
intrinsic immunogenicity and may explain the low re-
sponse rates to immunotherapy in metastatic breast can-
cer [2, 5].
From a clinical translational point of view, these re-
sults strongly favor the spatial assessment of CD8+ T
cells together with PD-1/LAG-3 within metastatic tissue
if immune modulatory therapy is considered. In case of
synchronous metastases at different anatomical loca-
tions, biopsy material of either all metastatic sites or one
of clinically greatest importance, such as brain metasta-
ses, should be discussed. The value of a combined as-
sessment of PD-L1 and tumor-infiltrating lymphocytes
was recently proposed as a more comprehensive
immuno-oncological biomarker in breast cancer [29].
Whether our suggested evaluation of immune pheno-
types together with PD-1/LAG-3 within metastatic tissue
may serve as an even more comprehensive immuno-
oncological biomarker needs further validation in larger
and prospective cohorts.
Among the distant metastatic sites, brain and soft tis-
sue METs displayed more prevalently an inflamed but
exhausted immune phenotype. To distinguish site-
specific immune changes [14] from the molecular breast
cancer subtype, we included additional brain metastases.
Again PD-1+/LAG-3+ expression correlated to “hot”
brain METs regardless of the molecular breast cancer
subtype supporting our previous notion of a tumor in-
trinsic immunogenicity.
In our cohort, an inflamed PD-1−/LAG-3− immune
phenotype in the PBT was associated with an improved
DFS implying a negative DFS prognostic impact of PD-
1/LAG-3 expression. While this certainly needs to be
confirmed in a larger cohort, this adverse prognostic sig-
nificance of PD-1/LAG-3 expression was not unexpected
given their inhibitory effects on the immune response in
general [6]. Nevertheless, these observations were in
contrast to a recent publication describing improved
DFS in PD-1- and LAG-3-positive primary breast can-
cers [23].
In recent reports, LAG-3 expression is associated with
different DFS prognostic outcomes which may be due to
a small number of LAG-3/PD-1 positive cases,
heterogenous methods employed, and different LAG-3-
positive cutoffs [9]. While Burugu et al. [23] used tissue
microarrays (TMAs) and focused on intratumoral lym-
phocytes, the paper by Bottai et al. [28] described data
using whole slides and stromal lymphocytes. This illus-
trates the inconsistencies and limitations between
methods and the tumor compartment evaluated. TMAs
are usually constructed using only small tumor cores
taken in regions with high tumor content and not se-
lected based on the presence of abundant immune infil-
tration. TMAs may as such neither reflect the
intratumoral heterogeneity nor give the complete picture
of the presence of LAG-3-positive cells as the whole tis-
sue sections we used. Furthermore, due to our interest
in LAG-3 and PD-1 expression in metastatic tissue, our
cohort is biased for patients with advanced metastatic
disease thus differing from an average breast cancer
cohort.
Our study fills an important knowledge gap in meta-
static breast cancer in two main regards: (i) the immune
phenotype and PD-1/LAG-3 expression within
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metastatic breast cancer are significantly different from
the primary tumor and among anatomical metastatic
sites and (ii) PD-1+/LAG-3+ expression is strongly asso-
ciated with a “hot” immune phenotype. Taken together,
not the primary tumor but metastatic breast cancer
should be analyzed for the immune phenotype and PD-
1/LAG-3 expression to reveal the metastasis-associated
immune pathology. This dual evaluation in metastatic
sites may eventually improve the stratification of ad-
vanced breast cancer patients for immunotherapy given
that CD8+ T cells must be present within the tumor bed
for an effective immunotherapy response [10].
Conclusions
In summary, LAG-3 was exclusively observed in PD-1+
cases with an overall low frequency. PD-1+/LAG-3+ ex-
pression was associated with a “hot” immune phenotype
both in PBTs and METs regardless of the breast cancer
molecular subtype. Disease-free survival was significantly
improved in inflamed but PD-1−/LAG-3− PBTs. In our
cohort, METs of “cold” PBTs always remained “cold” at
their matched metastatic site. In contrast, “hot” PBTs ei-
ther remained “hot” or turned “cold” in their corre-
sponding METs. Among the anatomical sites of
metastases, brain and soft tissue metastases were more
commonly inflamed with signs of exhaustion.
Our study emphasizes the careful assessment of the
immune phenotype and PD-1/LAG-3 expression in
metastatic breast cancer tissue to overcome intrapatient
tumor heterogeneity. Furthermore, analysis of metastatic
breast cancer tissue may improve the stratification of ad-
vanced breast cancer patients for a dual anti-PD-1/anti-
LAG-3 immunotherapy.
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